ADVA
ADVA (FSE: ADV) today announced that Serverius, one of the Netherlands’ largest data center service suppliers, is leveraging its FSP 3000 TeraFlex™ terminal to massively increase the capacity of its deployed infrastructure. By utilizing the industry’s most comprehensive and scalable solution, Serverius is answering fierce growth in demand for its connectivity, colocation and data security services. With its ultra-flexible bandwidth modulation, TeraFlex™ enables Serverius to harness previously unused spectrum, unlocking new value in its existing fiber network. The highly compact 1RU platform optimizes all optical paths and ensures the lowest cost per bit for all fiber links. By enabling super-channels of up to 1200Gbit/s and a total capacity of 7.2Tbit/s, TeraFlex™ empowers Serverius to provide Dutch and international enterprises with a new level of capacity and throughput.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200409005014/en/
“By harnessing the very latest innovation, we’re bringing a new level of bandwidth capacity and service quality to businesses throughout the Netherlands and beyond. The ADVA FSP 3000 TeraFlex™ is key to our mission of providing world-class data center connectivity. And, with its space- and power-efficiency, it also ensures that our services remain highly affordable today and sustainable for the future,” said Sergey Petukhin, head of connectivity infrastructure, Serverius. “This deployment unlocks the full potential of our network. Now we can meet rapidly rising data demand and be sure that our infrastructure is ready to scale when our clients need even more capacity. What’s more, the openness and programmability of TeraFlex™ mean that we’re free to harness the benefits of tomorrow’s innovation without being tied to any one vendor.”
Serverius’ new solution is built on the ADVA FSP 3000 TeraFlex™, which uses software-defined fractional QAM modulation and adaptive baud rate capabilities to support 1200Gbit/s streams. By retrieving optical channel conditions via network telemetry, the platform determines the best possible capacity and spectral efficiency for each light path. This enables Serverius to exploit untapped capacity in its existing infrastructure without the cost of a complete system upgrade. Each 1RU terminal can also support up to three cards, providing easy access to capacity up to 7.2Tbit/s. What’s more, Serverius is also harnessing ADVA’s MicroMux™QSFP28 plug, which converts 100GbE client ports into ten 10GbE ports, further reducing cost, rack space and operational complexity. Cloud solution specialists Exclusive Networks also played a key role in deploying the technology.
“Serverius has a clear vision of what businesses need and a bold strategy for delivering it. By leveraging our most advanced technologies to massively increase the capacity of its fiber plant, the Netherlands’ fastest-growing cloud connectivity provider is offering its customers a vital competitive edge. With our TeraFlex™, Serverius has the power to flexibly respond to soaring data requirements and help businesses achieve their full potential,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “The strong and long-lasting relationship we have with the Serverius team was also crucial to the success of this project. By working closely with their people, we’ve been able to ensure that the new solution meets all of their particular needs while maximizing the value of their deployed infrastructure.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200409005014/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FIM Partners and Loomis Sayles Announce Transition of Global Emerging Market Equities Team6.11.2025 14:00:00 CET | Press release
FIM Partners today announced it has entered into an agreement with Loomis, Sayles & Company, to acquire the Global Emerging Market Equities (GEM) investment team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106799715/en/ Overview of the GEM Team and FIM Led by Ashish Chugh, Portfolio Manager and Head of Global Emerging Market Equities, the GEM Team follows a high conviction investment philosophy anchored in deep, fundamental research and a private equity-style approach to diligence and ownership. The team invests in high quality companies and those transitioning toward higher quality, leveraging its proprietary insights to identify long-term value creation opportunities across emerging markets. With an active, bottom-up, benchmark-agnostic strategy, the team builds high-conviction, concentrated, quality-focused portfolios that reflect a true ownership mindset. Founded in 2008, FIM Partners is a leading asset manager fo
IFCO’s circular model delivers global impact: Five years of progress marked with 2025 ESG report6.11.2025 14:00:00 CET | Press release
Over 10 billion single-use boxes replaced with reusable packaging in global fresh grocery supply chains IFCO, a global leader in reusable packaging containers (RPCs) for fresh food, today published its ESG Report 2025, marking the successful completion of its five-year sustainability strategy, Thriving in the Circular Economy. Over the last five years, IFCO has advanced every one of its 18 ESG goals, delivering measurable progress for the planet, people, partners, and customers while laying the groundwork for the next iteration of its sustainability objectives. The ESG Report 2025 confirms IFCO’s position as a global leader in circular packaging and highlights the role of reuse in addressing some of the sector’s most pressing challenges. Since IFCO’s founding in 1992, it has dedicated itself to eliminating packaging and food waste in the fresh grocery supply chain, enhancing efficiencies across the value chain and sharing the resulting long-term value with stakeholders. With operations
Debiopharm Takes a Step Forward for Children With CPP: Enrollment Completion for the Phase III Trial Evaluating the First Ever Yearly Injectable Triptorelin Formulation6.11.2025 14:00:00 CET | Press release
LIBELULATM trial completed enrollment of Central Precocious Puberty (CPP) patients in North and South America, advancing the path for Debio 4326, a triptorelin injectable 12-month extended-release formulation Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality of life, today announced the successful completion of patient enrollment in its open-label, single-arm, multi-center Phase III study (NCT06129539) ‘A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULATM)’. The completion of enrollment is a significant milestone for the development of Debio 4326, a unique injectable, biodegradable 12-month extended-release formulation of the established treatment, triptorelin. The LIBELULATM trial is being conducted across the United States, Argenti
U.K. Continues to Lead Europe in Shareholder Activism with 44% Year-on-Year Surge, According to Diligent Market Intelligence6.11.2025 13:00:00 CET | Press release
As the U.K. Market Fuels Growing Interest from Domestic and International Activists, Investors Have Adapted their Approach to Gain Access to Boardrooms in Germany and Italy The U.K. remains Europe’s most active market for shareholder activism, with a 44% year-on-year increase in targeted companies, according to the Corporate Governance in Europe 2025report by Diligent Market Intelligence (DMI). Between September 2024 and August 2025, 52 U.K. companies faced activism, compared to 36 over the same timeframe in 2024, underscoring the market’s heightened shareholder engagement. “The U.K. remains the primary driver of public-facing engagement in Europe, with other European markets increasingly witnessing similar strategies when behind-the-scenes efforts fail,” said Josh Black, Editor-in-Chief, Diligent Market Intelligence. “Activism in Europe runs the full gamut from hostile media campaigns to more private engagements but there is no doubt that boards should prepare for anything in what loo
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates6.11.2025 12:00:00 CET | Press release
Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024Global BRUKINSA® (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024Diluted GAAP Earnings per American Depository Share (ADS) of $1.09, non-GAAP diluted Earnings per ADS of $2.6547 abstracts accepted at American Society of Hematology (ASH) Annual Meeting BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. “These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “BRUKINSA is now the global revenue leader in the BTKi class, supported by long-term efficacy and safety data and a growing body of evidence reinforcing its scientific hypothesis of sustained BTK inhibition. Our late-stage hematology portfolio continues
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom